<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04383808</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-55044</org_study_id>
    <nct_id>NCT04383808</nct_id>
  </id_info>
  <brief_title>Clinical Translation of a Novel Brain PET Insert for Simultaneous PET/MR</brief_title>
  <official_title>Clinical Translation of a Novel Brain PET Insert for Simultaneous PET/MR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this project is to study the feasibility of a brain-dedicated PET insert
      for an MR scanner for simultaneous acquisition of PET/MR images of human brains. The study
      will also allow us to compare the imaging performance of the investigator's brain-dedicated
      PET insert against a commercial whole-body permanently integrated PET/MRI system using a
      common radiopharmaceutical.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll up to 40 participants.

        1. 20 participants at Stanford injected with an FDA-approved PET tracer (e.g. amyloid, FDG,
           etc.), and

        2. 20 participants from Stanford who have been pre-injected with a radiopharmaceutical for
           a study on another PET imaging system
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PETMR image</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The key specific measurement is the resulting PET/MR image obtained from the single subject scan.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Brain Disease</condition>
  <arm_group>
    <arm_group_label>Arm-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 participants will be recruited, inject with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 participants will be recruited from other imaging studies that have been already injected (pre-injected) with a radiopharmaceutical. These subjects wont receive an additional injection of radiopharmaceutical.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Injected radiotracer with PET Insert</intervention_name>
    <description>Informed consent will be obtained before beginning any study procedures.
Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed.</description>
    <arm_group_label>Arm-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Pre-injected group with PET insert</intervention_name>
    <description>Informed consent will be obtained before beginning any study procedures.
Participants who have received radiotracer for another PET imaging system. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed.</description>
    <arm_group_label>Arm-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Whole body radiation dose within the last year of less than 5000 mrem

          2. Subjects intended for injected tracer studies (not associated with another study) must
             be willing/able to undergo injection of 6-12 mCi of either FDG or Neuraceq
             radiotracer. Both tracers are FDA approved

          3. Subjects will be at least 21 years of age

          4. Subject provides written informed consent

          5. Subject is deemed healthy by the PI by via self-reported questionnaire

        Exclusion Criteria:

          1. For patients who will be receiving a tracer injection, no known allergy to the imaging
             agents

          2. Participant has a history of or current diagnosis of cancer

          3. Participant is pregnant or nursing

          4. Metallic implants (contraindicated for MRI)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Marcellus</last_name>
    <phone>650-723-4547</phone>
    <email>dmarcel2@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David Marcellus, BS</last_name>
      <phone>650-723-4547</phone>
      <email>dmarcel2@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Craig Levin</investigator_full_name>
    <investigator_title>Professor, Radiology/ Nuclear Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

